-
Sector Analysis
Head and Neck Squamous Cell Carcinomas (HNSCC) – Cell and Gene Therapies 15-Market Assessment and Sales Forecast to 2031
The Head and Neck Squamous Cell Carcinomas (HNSCC) market size for the 15 markets (15M) was $1.9 billion in 2021. HNSCC have an active cell therapy pipeline and one of the largest gene therapy/oncolytic virus clinical pipelines across all oncology indications. HNSCCs are characteristically aggressive tumors, disseminating relatively early, as observed in the high rates of metastatic disease at diagnosis. Late-stage cases constitute around 60% of all HNSCC cases. The growth of the primary tumor is associated with the presence...
-
Sector Analysis
Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Assessment and Sales Forecast to 2031
Glioblastoma Multiforme Market Report Overview The Glioblastoma Multiforme market value for the 15 markets (15M) was $630 million in 2021. This included both CGTs and established/traditional GBM therapies. The Glioblastoma Multiforme market research report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early to late clinical-stage pipeline products, with a launch date assessment by the market for...
-
Sector Analysis
![]()
Multiple Myeloma – Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Explore in-depth market insights from the following data in our ‘Multiple Myeloma Cell Therapy Market’ report: Access updated epidemiology for patient populations relevant to cell therapy in 2021-2031 Review updated prescription habits at the class level for already established therapies (defined in our analysis as chemotherapy, targeted therapies, and others [such as immune checkpoint inhibitors or hormone therapies]) and compare their future projections to cell therapy pipeline drugs Full market assessment in the 8MM of all currently marketed and late-stage pipeline cell therapy drugs with drug-level forecasts, supplemented by class-level forecasts for early-stage molecules Explore indication-specific top-line sales forecasts across 15 countries, in the 8MM and...
-
Sector Analysis
Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Chronic Lymphocytic Leukemia (CLL) Market Report Overview The Chronic Lymphocytic Leukemia (CLL) market value for the 15 markets (15M) was $13.2 billion in 2021. This included both cell therapies and established/traditional CLL therapies. The 15 markets comprise the 8 major markets and seven countries known to have increased potential for cell therapies given the current drug development landscape, namely Australia, South Korea, Belgium, Denmark, Switzerland, Israel, and Canada. The CLL market research report provides an analysis of the key dynamics...
-
Sector Analysis
Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Accessing in-depth insights from the ‘Acute Lymphocytic Leukemia Cell Therapy Market’ report will help you: Assess the disease epidemiology and 10-year patient-based forecast (PBF) across the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China) and identify the potential countries for growth opportunities within the ALL-cell therapy market. Analyze the clinical and commercial landscapes of each indication, with pricing assumptions Evaluate indication-specific unmet needs and competitive assessments by Class of Therapy Identify the Likelihood of Approval Analysis...
-
Sector Analysis
Colorectal Cancer Cell and Gene Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2031
Colorectal Cancer Market Report Overview The Colorectal Cancer (CRC) 15 (CGT and established/conventional therapies) market size was $18.9 billion in 2021. CRC has one of the largest gene therapy/oncolytic virus clinical pipelines across all of oncology, and a relatively active clinical cell therapy pipeline compared to other solid tumors. There are currently no marketed or Phase III CGT agents in CRC, reflecting the difficulties of progressing these drug types into the CRC market. This is largely due to insufficient efficacy; however, there...
-
Thematic Analysis
![]()
Impact of Brazil on the Pharmaceutical Industry – Thematic Intelligence
Brazil Pharmaceutical Market Report Overview Brazil is the largest pharmaceutical market in Central/Southern America and is the 12th largest in the world. Brazil is an untapped market for big pharma manufacturing, with domestic companies dominating the marketed products landscape. The domestic pharmaceutical companies will continue to grow due to favorable policies provided by the Brazilian government to promote domestic production of medicines. Furthermore, over the years, Brazil has elevated its infrastructure, scientific, and technological facilities and has created a sustainable...
-
Sector Analysis
B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2021-2031
Access and explore the following in-depth insights from the ‘B-Cell Non-Hodgkins Lymphoma Cell Therapy Market’ report: Disease epidemiology including - Patient segmentation, staging & progression rates, and Disease incidence/prevalence. Marketed products with a breakdown established versus cell therapies, backed with primary research validated base year forecast Commercial assessment and Forecast by number of patients treated per class and future sales projection based on competitive assessment Launch date assessment with estimated launch dates by class of cell therapy and indication-specific assumptions. Evaluation...
-
Sector Analysis
Acute Myeloid Leukemia Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2031
Acute Myeloid Leukemia Market Report Overview The AML market value for the 15 markets (15M) was $3.1 billion in 2021. Acute myeloid (or myelogenous or myelocytic) leukemia (AML) is a malignancy of the hematopoietic system caused by the abnormal proliferation or differentiation of myeloid progenitors in the bone marrow and peripheral blood. AML is relatively rare and has a poor prognosis, particularly in elderly patients. The first approval for cell therapy drugs is anticipated in 2023, which is expected to positively...
-
Thematic Analysis
![]()
Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2022 Update
Since the first case of COVID-19 was diagnosed in Wuhan, China, in December 2019, COVID-19 cases rose rapidly across the globe. On March 11, 2020, World Health Organization (WHO) officially declared that COVID-19 is a pandemic. Over 1,200 clinical trials worldwide have either been disrupted by COVID-19 due to suspended enrollment or delayed initiation or have been impacted by slow enrollment. Regulatory guidance has been issued for industry, investigators, and institutional review boards on conducting clinical trials during the COVID-19...
-
Sector Analysis
Niemann-Pick Type C Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
The Niemann-Pick Type C (NPC) market size was $128.35 million in 2021 and is forecast to achieve a CAGR of more than 3% during the forecast period. Major symptoms of the disease are neurological and developmental disorders, as well as hepatosplenomegaly, jaundice, cholestasis, bleeding disorders, and eventually dysphagia and even respiratory failure in adults. Early diagnosis remains a critically unmet need, with many patients receiving a diagnosis late after the onset of neurological disease and other musculoskeletal disabilities.
-
Sector Analysis
Bronchiectasis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
The Bronchiectasis market size was valued at $408.2 million across the 3MM in 2021. The market is expected to grow at a CAGR of more than 8% during the forecast period. AMD is one of the leading causes of irreversible vision loss. Bronchiectasis is defined by the damage to the bronchi, causing abnormal dilation and scarring. The airways become inflamed with thick mucus that is difficult to clear, whose build up creates an environment for bacterial growth. This uncontrolled bacterial...
-
Thematic Analysis
![]()
Electronic Health Records – Analyzing Trends, Technologies, Use Barriers, and Future Prospects
Electronic Health Records (EHRs) have long been touted as a key element for achieving more efficient healthcare. One of the primary aims of EHRs was to improve data flow within healthcare systems, to enhance day-to-day operations and patient care. With EHRs becoming more integrated and technologically advanced, and an increasing number of governments supporting their nationwide implementation, EHR uptake has grown significantly. Nevertheless, several issues, including a lack of standardization, interoperability, data safety, and user acceptance, have emerged as obstacles for their...
-
Sector Analysis
Alport Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
The Alport syndrome pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products, late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR), and Likelihood of Approval (LoA) for Alport syndrome. Â The report also analyzes the clinical and commercial landscapes of Alport syndrome, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment. Alport syndrome (AS) is a genetically and phenotypically heterogeneous, progressive hereditary renal disease that is...
-
Sector Analysis
Renal Cell Carcinoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule. RCC is the most common type of kidney cancer in adults. While it is considered one of the most lethal urological cancers, the causes of RCC are largely unknown. The most important known etiological risk factors, all of which are modifiable, are tobacco use, high blood pressure, and obesity. The renal cell carcinoma marketed and pipeline drugs market report provides...
-
Sector Analysis
Smoking Cessation Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Cigarette smoking increases the risk of various respiratory and cardiac diseases and is the biggest contributor to the tobacco epidemic, a serious public health threat that kills more than 8 million people a year around the world. Nicotine dependence is recognized as a medical condition in the Diagnostic and Statistical Manual (DSM) of the American Psychiatric Association, and tobacco dependence is recognized in the International Classification of Diseases (ICD). Smoking cessation is defined as the continued dependence on nicotine following...
-
Sector Analysis
Alpha-1 Antitrypsin Deficiency Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
Alpha-1 Antitrypsin Deficiency Market Report Overview The Alpha-1 Antitrypsin Deficiency (AATD) market size in the 2MM (US and Germany) was valued at $1.36 billion in 2021 and is forecast to grow at a CAGR of more than 12% during the forecast period, 2021-2031. The introduction of 4 new pipeline agents are key drivers of this market growth. AATD is an inherited disease that causes an increased risk of chronic obstructive pulmonary disorder (COPD), hepatic failure, skin problems (panniculitis), and inflammation...
-
Sector Analysis
Food Allergy Market Size and Trend Report including Marketed and Pipeline Drug Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast to 2030
Food Allergy Market Overview The food allergy market was valued at $213.9 million in 2020 globally and is forecast to grow at a CAGR of more than 28% during the forecast period. Food Allergy Market Overview, 2020-2030 ($Million) For more insights into the food allergy market forecast, download a free report sample The food allergy market lacks a curative agent, with the only available treatments being antihistamines or epinephrine usage for accidental exposure. The food allergy pipeline consists of 31...
-
Sector Analysis
Sarcoidosis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
The sarcoidosis marketed and pipeline drugs assessment reports provides a data-driven overview of the current and future competitive landscape in sarcoidosis therapeutics. Sarcoidosis usually presents with persistent dry cough, eye and skin manifestations, weight loss, fatigue, night sweats, and erythema nodosum. Various factors including infection, genetic predisposition, and environmental factors are involved in the pathology of sarcoidosis. Exposures to insecticides, herbicides, bioaerosols, and agricultural employment are associated with an increased risk for sarcoidosis. An early and accurate diagnosis of sarcoidosis...
-
Sector Analysis
Osteosarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
The osteosarcoma marketed and pipeline drugs assessment report provides a data-driven overview of the current and future competitive landscape in osteosarcoma therapeutics. Osteosarcoma is the most common primary pediatric bone malignancy, derived from primitive bone-forming mesenchymal cells, and is characterized by extensive and heterogeneous genetic complexity. Osteosarcoma can be classified into various subtypes according to the degree of differentiation, location within the bone, and histological variation. Osteosarcoma can also be subdivided into primary and secondary forms. Primary tumors usually occur...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.